-
Product Insights
NewPontine Glioma – Drugs In Development, 2024
Empower your strategies with our Pontine Glioma – Drugs In Development, 2024 report and make more profitable business decisions. Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, drooping of one side of the face, and difficulty...
-
Product Insights
NewLiposarcoma – Drugs In Development, 2024
Empower your strategies with our Liposarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Liposarcoma is a rare tumor derived from fat tissue that occurs in the “soft tissues” of the body (soft tissue sarcoma). It is classified as a cancer (malignant) because of its potential to recur locally and spread to other areas of the body. The severity of disease depends on the subtype of the liposarcoma and the presenting stage of the primary tumor....
-
Product Insights
NewNon-Rhabdomyosarcoma – Drugs In Development, 2024
Empower your strategies with our Non-Rhabdomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Non-rhabdomyosarcoma refers to a group of cancers that are distinct from rhabdomyosarcoma, a type of soft tissue cancer that arises from skeletal muscle cells. Non-rhabdomyosarcoma includes various types of soft tissue sarcomas that originate in tissues such as nerves, blood vessels, fat, and connective tissues. These sarcomas can occur in different parts of the body, and their characteristics and treatment approaches vary. Common...
-
Product Insights
NewDengue Fever – Drugs In Development, 2024
Empower your strategies with our Dengue Fever – Drugs In Development, 2024 report and make more profitable business decisions. Dengue is a mosquito-borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from the nose, gums, or under the skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of...
-
Product Insights
NewCutaneous T-Cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Cutaneous T-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Cutaneous T-cell lymphoma (CTCL) is a rare type of cancer that begins in white blood cells called T cells (T lymphocytes). These cells normally help body's germ-fighting immune system. In cutaneous T-cell lymphoma, the T cells develop abnormalities that make them attack the skin. Originating in T lymphocytes, it causes skin alterations like red, scaly patches or itchy plaques, progressing slowly...
-
Product Insights
NewZika Virus Infections – Drugs In Development, 2024
Empower your strategies with our Zika Virus Infections – Drugs In Development, 2024 report and make more profitable business decisions. Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can also be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain...
-
Product Insights
NewBrain Cancer – Drugs In Development, 2024
Empower your strategies with our Brain Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Brain cancer refers to the abnormal growth of cells in the brain, forming tumors that can be benign (non-cancerous) or malignant (cancerous). Primary brain tumors originate in the brain itself, while secondary tumors result from the spread of cancer from other parts of the body. Symptoms may include headaches, seizures, changes in behavior, and cognitive impairment. Diagnosis involves imaging studies like MRI...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LN-145S1 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LN-145S1 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LN-145S1 in Non-Small Cell Lung Cancer Drug Details: LN-145-S1 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ASC-41 in Non Alcoholic Fatty Liver Disease (NAFLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASC-41 in Non Alcoholic Fatty Liver Disease (NAFLD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ASC-41 in Non Alcoholic Fatty Liver Disease (NAFLD)Drug Details:ASC-41...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PXS-6302 in Burns
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PXS-6302 in Burns Drug Details: PXS-6302 is under development for the treatment of scarring...